All Projects

ETIMSred

Establishing immune tolerance in multiple sclerosis with peptide-coupled red blood cells

Wysszurich keyvisual etimsred

Potential

The purpose of ETIMSred is to develop a long-lasting therapy for multiple sclerosis (MS) that specifically targets the harmful autoimmune response without affecting the rest of the immune system.

Project Description

With approximately 2.5 million patients worldwide, multiple sclerosis (MS) is one of the most common causes of permanent neurological disability in young adults.

So far, there is no cure for MS. Current treatments merely reduce the incidence of disease relapse, and they carry the risk of severe side effects caused by inhibiting the patient’s immune system. What is needed is a long-lasting therapy that will specifically target the harmful autoimmune response without affecting the rest of the immune system.

A team led by Professor Roland Martin has developed an innovative therapy known as ETIMS (Establish Tolerance in MS). This therapy employs the patient’s white blood cells, chemically coupling them with myelin peptides. These altered blood cells then target the immune cells responsible for inflammation and stop the autoimmune process by educating the immune system to tolerate structures such as myelin. This approach has been successfully tested in MS patients in a first-in-man trial.

At Wyss Zurich, the ETIMSred team has advanced this therapy by using red instead of white blood cells to induce immune tolerance. Since it is easier to collect a large number of red blood cells from patients, this approach has substantially improved the feasibility of the treatment. A key objective of the ETIMSred project is also to establish the safety, tolerability, and efficacy of this new approach in a Phase I/II clinical trial in MS patients.

ETIMSred’s startup company Cellerys signed a cooperation agreement with Novartis in June 2021. Novartis will now support further development of the therapy, which is currently in a Phase II clinical trial.

Contact

Cellerys AG
+41 41 544 98 80
info@cellerys.com

Faculty Mentor

Roland Martin

Portrait roland 560

Achievements

06/2022
Wyss Zurich project completion

The project ETIMSred exits Wyss Zurich and continues operations in its startup company Cellerys AG.

06/2021
Cellerys enters cooperation with Novartis

Novartis has signed a cooperation agreement and an option to acquire Cellerys

08/2020
Extension of Phase Ib clinical trial completed

The last patient in the Phase Ib extension study was treated.

12/2018
Completion of Phase Ib clinical trial

All patients in the Phase Ib trial have been treated.

10/2017
Phase Ib clinical trial start

The Phase Ib headed by Professor Andreas Lutterotti starts in October 2017.

11/2015
Cellerys AG incorporation

The UZH spin-off ETIMSred is incorporated under the name Cellerys AG.

10/2015
Wyss Zurich admission

ETIMSred is accepted as full project.

Core Team

Andreas lutterotti portrait

Andreas Lutterotti

Project Leader

Maria jose docampo portrait

Maria Jose Docampo

Scientist

Magdalena foege portrait

Magdalena Foege

Regulatory Affairs Expert

Mireia sospedra portrait

Mireia Sospedra

Senior Scientist

Do you have a breakthrough project you want us to know about?

We urge you to contact the Wyss Zurich office to discuss your project and start the evaluation process.